Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2021-11-24 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure, which relates to changes in capital structure and financial instruments (convertible bonds), falls under the category of capital and financing updates.
2021-11-24 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Daewon Pharmaceutical, covering the period from 2021.01.01 to 2021.09.30. It contains detailed financial statements, management discussion, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity's shareholding in a listed company crosses a specific threshold (typically 5%). This is a standard disclosure document for major shareholders, categorized as a Major Shareholding Notification.
2021-08-31 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory disclosure from Daewon Pharmaceutical regarding its 'Compliance Program' (CP) operations, detailing past performance and future plans. This type of disclosure, which provides information on internal governance and regulatory compliance programs, does not fit into specific financial reporting categories like 10-K or IR. It is a general regulatory announcement filed with the exchange, making 'RNS' (Regulatory Filings) the most appropriate classification.
2021-08-27 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Daewon Pharmaceutical, covering the period from January 1, 2021, to June 30, 2021. It contains comprehensive financial statements, management discussion, and operational details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-17 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the issuance results of convertible bonds (a type of capital financing). It specifies the issuance amount, payment date, and confirms the completion of the transaction. This falls under the category of capital/financing updates.
2021-05-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.